Displaying all 3 publications

Abstract:
Sort:
  1. Othman N, Vitry AI, Roughead EE
    BMC Public Health, 2010;10:294.
    PMID: 20509953 DOI: 10.1186/1471-2458-10-294
    BACKGROUND: Journal advertising is used by pharmaceutical companies to disseminate medicine information to doctors. The quality of claims, references and the presentation of risk results in Australia and the US has been questioned in several studies. No recent evidence is available on the quality of claims, references and the presentation of risk results in journal advertising in Australia and the US and no Malaysian data have been published. The aim of this study was to compare the quality of claims, references and the presentation of risk results in journal advertising in these three countries.
    METHODS: A consecutive sample of 85 unique advertisements from each country was selected from journal advertising published between January 2004 to December 2006. Claims, references and the presentation of risk results in medical journal advertising were compared between the three countries.
    RESULTS: Less than one-third of the claims were unambiguous claims (Australia, 30%, Malaysia 17%, US, 23%). In Malaysia significantly less unambiguous claims were provided than in Australia and the US (P < 0.001). However, the unambiguous claims were supported by more references than other claims (80%). Most evidence was obtained from at least one randomized controlled trial, a systematic review or meta-analysis (Australia, 84%, Malaysia, 81%, US, 76%) with journal articles being the most commonly cited references in all countries. Data on file were significantly more likely to be cited in the US (17%) than in Australia (2%) and Malaysia (4%) (P < 0.001). Advertisements that provided quantitative information reported risk results exclusively as a relative risk reduction.
    CONCLUSIONS: The majority of claims were vague suggesting poor quality of claims in journal advertising in these three countries. Evidence from a randomized controlled trial, systematic review or meta- analysis was commonly cited to support claims. However, the more frequent use of data that have not been published and independently reviewed in the US compared to Australia and Malaysia raises questions on the quality of references in the US. The use of relative rather than absolute benefits may overemphasize the benefit of medicines which may leave doctors susceptible to misinterpreting information.
    Matched MeSH terms: Advertising as Topic/standards*
  2. Teoh SK
    N Y State J Med, 1983 Dec;83(13):1317-9.
    PMID: 6582387
    Matched MeSH terms: Advertising as Topic/standards*
  3. Chan SP, Chui WC, Lo KW, Huang KC, Leyesa ND, Lin WY, et al.
    Asia Pac J Public Health, 2012 Jul;24(4):641-9.
    PMID: 21490107 DOI: 10.1177/1010539511402189
    The increasing prevalence of overweight and obesity worldwide demands increased efforts in the prevention and management of obesity. This article aims to present consensus statements promoting appropriate consumer education and communication programs for weight-loss agents in Asia.
    Matched MeSH terms: Advertising as Topic/standards
Related Terms
Filters
Contact Us

Please provide feedback to Administrator ([email protected])

External Links